China Medical GatewayLoading your healthcare gateway…

Hospital of Hematology, Chinese Academy of Medical Sciences

Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin

Hospital Profile

The Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) was established in 1957 by Professor Deng Jiadong, one of the founders of hematology in China. It moved to Sichuan in the 1970s and was relocated back to Tianjin in 1982. It currently has three campuses: Haiguangsi, Tuanbo, and Huayuan. It is the country's only national top-tier (Grade III, Class A) specialized hematology hospital and is currently the largest national research-based specialized medical institution for hematological diseases in China, integrating medical treatment, research, teaching, and industry. It is also the world's largest hematology center, aiming to develop into an internationally leading hub for hematology innovation and health. It houses multiple national-level platforms, including the National Clinical Research Center for Hematologic Diseases, the National Key Laboratory of Hematology and Health, the National Quality Control Center for Hematology (in preparation), the National “Belt and Road” Joint Laboratory, the National Engineering Research Center for Stem Cells, the National Engineering Research Center for Cellular Products, and the National Industrialization Base for Stem Cell Engineering Products. It is a top institution in China for the diagnosis and treatment of hematological diseases.

Medical Milestones

Founded in 1957, it moved to Sichuan in the 1970s and returned to Tianjin in 1982. Since its establishment, the institute has accumulated 24 national-level awards. It founded the "Chinese Journal of Hematology" and the first and only English hematology journal in China, "Blood Science." In 2012, Peking Union Medical College established China's first Department of Stem Cell and Regenerative Medicine based on the institute. Since completing China's first autologous hematopoietic stem cell transplant, the institute has continued to focus deeply on the field of stem cells, creating the "Tianjin Model" for the application and transformation of stem cell technology. It promoted the official approval and launch of the innovative drug Naxioncel Injection (the first CAR-T product for leukemia to be approved and launched in China as a fully independent innovation). Since the 14th Five-Year Plan, the institute has been approved for research projects with a total funding of 930 million yuan, published 827 SCI papers, obtained 195 authorized patents, and achieved patent transformation revenue of over 120 million yuan. In 2024, the International Diagnosis and Treatment Center was officially approved for construction.

Key Capabilities & Patient Care

The institute closely focuses on the combination of basic and clinical research, adhering to the clear orientation of 'scientific problems originate from clinical practice, and research achievements serve patients.' It has complete specialties, including Red Blood Cell Disease Diagnosis and Treatment Center, Leukemia Diagnosis and Treatment Center, Thrombosis and Hemostasis Diagnosis and Treatment Center, Stem Cell Transplantation Center, Lymphoma Diagnosis and Treatment Center, MDS and MPN Diagnosis and Treatment Center, Pediatric Hematology and Oncology Diagnosis and Treatment Center, Hematology Emergency Center, Immune Cell Therapy Center, GCP Center, Regenerative Medicine Diagnosis and Treatment Center, Critical Care Diagnosis and Treatment Center, Radiotherapy Center, and Hematopathology Diagnosis Center, Clinical Testing Center, among others. As a teaching unit of Peking Union Medical College, upholding the educational principle of elite education, it currently has three world-class disciplines in Clinical Medicine, Pharmacy, and Biology, with six doctoral programs, seven master's programs, and one postdoctoral workstation, with 358 students currently enrolled. It has established a five-in-one hematology training system integrating clinical, nursing, pathology testing, basic research, and clinical trials, accepting an average of about 400 trainees annually. The institute actively explores models for the translation of scientific and technological achievements.

Advanced Technology

The institute has a total of 1,670 on-the-job employees, including 253 senior professional technical personnel; it has 55 doctoral supervisors and 38 master's supervisors. • Bed capacity: 1,267 beds actually open • Total staff: 1,670 on-the-job employees • Inpatients: Annual total not disclosed; estimated at about 18,000–22,000 per year (average hospital stay for hematology patients is about 22 days) • Outpatient and emergency visits: Annual service volume has exceeded 300,000 visits • Inpatient and elective surgeries: No routine surgical procedures; focuses on hematopoietic stem cell transplantation (the "Tianjin model"), with several hundred transplants annually; primarily CAR-T and other cell therapies • Number of senior title physicians: Not disclosed; official total not disclosed; estimated at about 200–267 people (this is an estimate, not official data, calculated based on 1,670 employees × 12%-16%)

International Patient Services

Adhering to an international development path, we have carried out substantial cooperation with internationally renowned academic institutions, established multiple international cooperation centers, and built platforms for high-level talent training and exchange. In 2024, the International Diagnosis and Treatment Center was officially approved for construction and successfully connected with countries along the Belt and Road, including Saudi Arabia, the United Arab Emirates, Belarus, and Thailand, opening up international medical channels. So far, 14 foreign patients have been treated, and there are further plans to promote the overseas application of more cell and gene therapy products and innovative technologies with independent intellectual property rights.

Return to Home